Sectors

Novo and Orlando Health helped the haemodialysis technology provider increase its overall funding to $350m since it was spun off by IMI.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Oshri Kaplan, director, Munich Re Ventures

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Intel Capital-backed customer experience software provider Sprinklr floated below its range in its initial public offering.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.

LinkedIn's data streaming spinoff, Confluent, is floating above its range in an offering effectively doubling the valuation of its last funding round to over $9bn.

The Tencent-backed social media app developer was aiming to raise $198m in the offering but has withdrawn in favour of alternative financing options.

PayPal and Visa have backed Blockchain Capital’s fifth flagship fund, which received $300m of commitments and which will focus on blockchain technology and cryptocurrencies.